Business Segments Caplin Point Laboratories Limited NSE India S.E.
Stocks
CAPLIPOINT
INE475E01026
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,649.20 INR | +1.34% |
|
+2.54% | +44.13% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Pharmaceutical Formulations | 1.06TCr | 1.27TCr | 1.47TCr | 1.7TCr | 1.94TCr | |||||
Total Assets | 1.36TCr | 1.74TCr | 2.19TCr | 2.7TCr | 3.21TCr | |||||
Interest Expense | -1.59Cr | -70L | -78L | -78L | -61L | |||||
Income Tax Expense | 62Cr | 77Cr | 74Cr | 103.01Cr | 135.69Cr | |||||
CAPEX | -70Cr | -91Cr | -193.47Cr | -145.82Cr | -191.52Cr | |||||
EBT | 313.62Cr | 385.82Cr | 451.35Cr | 564.43Cr | 676.78Cr | |||||
D&A | 36Cr | 45Cr | 43Cr | 51Cr | 63Cr | |||||
Net Income | 242.27Cr | 299.84Cr | 376.26Cr | 457.09Cr | 536.31Cr |
Geographical Revenue Distribution History
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Rest of The World | - | - | - | - | 1.58TCr | |||||
Total Assets | - | - | - | - | 1.45TCr | |||||
EBT | - | - | - | - | 540.34Cr | |||||
United States of America (USA) | - | - | 205.34Cr | 304.94Cr | 354.51Cr | |||||
Total Assets | - | - | - | - | 580.09Cr | |||||
EBT | - | - | - | - | 40Cr | |||||
Unallocated | - | - | - | - | 96Cr | |||||
Total Assets | - | - | - | - | 1.18TCr | |||||
EBT | - | - | - | - | 96Cr | |||||
Latin America | - | - | 1.22TCr | 1.36TCr | - | |||||
Africa | - | - | 44Cr | 34Cr | - | |||||
Export | - | - | - | - | - | |||||
India | - | - | - | - | - |
Select your edition
All financial news and data tailored to specific country editions
